HUTCHMED Announces Share Capital Details

TipRanksNov 29 04:15 ET

Reported Thursday, HUTCHMED Confirms ORPATHYS (Savolitinib) Retains Spot On China's National Reimbursement Drug List

BenzingaNov 29 02:33 ET

AstraZeneca Partner's Orpathys Secures Renewal on China's Drug Reimbursement List

MT NewswiresNov 28 07:37 ET

Hutchmed's Lung Cancer Drug to Remain in China's National Reimbursement Drug List

MT NewswiresNov 28 07:31 ET

Express News | HUTCHMED Announces Continued Inclusion of Orpathys® (Savolitinib) in the National Reimbursement Drug List in China at Current Terms

ReutersNov 28 05:30 ET

HutchMed (China) (00013.HK): The renewal of the listing of Vosaroxin (Savolitinib) on the Chinese National Medical Insurance Pharmaceutical List was successful under the current terms.

Hutchmed (China) announced on November 28th that following the medical insurance renewal with the China National Medical Insurance Administration ("National Medical Insurance Administration"), Orpathys (selpercatinib) will continue to be included in the new version of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List" ("Medical Insurance Drug List") effective from January 1, 2025, maintaining the same terms as the current two-year agreement. Orpathys is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI). It was conditionally approved in China in June 2021.

Gelonghui FinanceNov 28 05:08 ET